Jason M. Broderick

Articles

Nadofaragene firadenovec published data show strong efficacy in BCG-unresponsive NMIBC

November 30, 2020

“These data published in the Lancet Oncology show that nadofaragene firadenovec, a first-of-its-kind therapy, may be an effective treatment option for BCG-unresponsive non-muscle invasive bladder cancer patients,” Colin P. N. Dinney, MD.